BioSpace News Archive

PRINCETON, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Agile Therapeutics, are expected to be approximately $45 million. In addition, Agile Th

Feb. 21, 2020 13:30 UTC MORRISVILLE, N.C.--( BUSINESS WIRE )-- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that Dr. Barry Borlaug, Chair for Research, Division of Circulatory Failure, Department of Cardiovascular Medicine at the Mayo Clinic has joined our scientific advisory board. Tenax CEO

Feb. 21, 2020 13:30 UTC Frequency Therapeutics to Present at the 40 th Annual Cowen Healthcare Conference WOBURN, Mass.--( BUSINESS WIRE )-- Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present a company overview at the Cowen 40 th Annual Healthcare C

Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, and which the company refers to as personalized or individualized, to fit each patient’s unique anatomy, announced today that management will present at the Cowen 40th Annual Health Care Conference in Boston.

LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the full year ended December 31, 2019 on Thursday, February 27, 2020 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss the full year financial results and provide a corporate update. To participate, please d

Following the outbreak of Covid-19 novel coronavirus, Zoomlion Heavy Industry Science and Technology Co, (01157.HK) - a leading Chinese maker of engineering and agricultural equipment - immediately setup a Prevention and Control Team led by President Mr. Zhan Chunxin to coordinate donations and support the construction of emergency hospitals while ensuring workplace safety for returning employees.

Harbour BioMed (HBM) today announced completion of a Phase 1 study of HBM9161, a fully human anti-FcRn monoclonal antibody, to evaluate its safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Chinese subjects

VAZALORE’s novel mechanism of action ensures consistent aspirin bioavailability with administration in both fasting and fed conditions

CANTEL MEDICAL CORP. (NYSE:CMD) will release the results for its second quarter ended January 31, 2020 on Thursday, March 5, 2020 before the market opens, and hold a conference call to discuss the results at 8:30 a.m. ET.

Afya Limited, or Afya announced it entered into a purchase agreement for the acquisition, through its wholly-owned subsidiary Afya Participações S.A., of 100% of the total share capital of Centro Universitário São Lucas, or UniSL.